Brain growth factors
Studied for effects on BDNF, a protein involved in nerve cell function.
Investigational · not FDA-approved
Educational information about a synthetic peptide studied mainly in Russia. It is not FDA-approved, and its cognitive benefits are not established.
Introduction
Semax is a synthetic peptide studied mainly in Russia for brain-related conditions. This page explains its background, the research behind it, its limitations and its status in the United States.
Semax is not an FDA-approved medicine, and its benefits for memory or focus have not been established in well-designed studies. If you have concerns about memory, concentration or fatigue, a medical evaluation helps find the cause.
Overview
Semax is a synthetic peptide of seven amino acids. It is based on a short fragment of ACTH (adrenocorticotropic hormone), modified so that it does not act like the hormone itself.
Background
Semax was developed in Russia, where it is registered for certain neurological uses. Most of the published research comes from Russian research groups, and it has not been evaluated by the FDA.
Mechanisms
These mechanisms come mainly from laboratory and animal studies.
Studied for effects on BDNF, a protein involved in nerve cell function.
Proposed effects on dopamine and serotonin systems.
Explored in animal models of reduced blood flow to the brain.
Next step
If you have concerns about memory, focus or fatigue, a medical evaluation helps find the cause and proven options.
Research
Semax has been studied for attention and memory in animals and in small human studies, and for recovery after stroke in clinical studies conducted mainly in Russia. These studies were small, often lacked independent replication and do not show that Semax improves memory or focus in healthy people.
Evidence
Few participants and short follow-up.
Most results come from the same research groups.
Large, well-designed trials are lacking.
Long-term safety has not been studied.
Experimental vs. proven
A proven medical indication requires well-designed trials reviewed by a regulatory agency, such as the FDA. Semax has no FDA-approved indication: laboratory, animal and small human results suggest areas for research, not treatments with established benefits.
Regulatory status
Semax is not approved by the FDA for any use. The FDA has raised safety concerns about its use in compounded drugs, and its eligibility for compounding was under review in 2026. An advisory committee recommendation is not an FDA approval.
Risks
Side effects have not been well characterized in large studies.
Reported in small studies.
Reported with nasal products.
Reported in small studies.
Possible changes in mood.
Possible changes in sleep.
Not studied.
Safety
Because Semax has not been studied in large trials, its interactions with medicines and its safety in many groups are unknown. It may not be appropriate if any of the following apply to you:
Evaluation
Memory, focus, sleep, mood and medications.
Conditions such as thyroid problems, sleep disorders or depression.
Diagnosed conditions are treated with established care.
FAQ
Clear answers to help you prepare.
No. Semax is not approved by the FDA for any use. It is registered in Russia for certain neurological uses.
This has not been established in well-designed studies, especially in healthy people. If you notice changes in memory or focus, a medical evaluation should come first.
It is not an approved treatment for any neurological disease in the United States. Neurological conditions need evaluation and treatment with established care.
Its safety has not been established in large studies, and its long-term effects and interactions with medicines are unknown.
This page is educational. It does not give doses, schedules or instructions; any decision about a medicine is made only by a licensed provider after an individual evaluation.
Information on this page is educational and does not replace medical evaluation. Treatment options are determined individually.